A promising trial result does not establish a safe way to switch from an existing medicine to an investigational one. Retatrutide’s phase 3 obesity research evaluates a specified product within a controlled study. It does not provide a universal conversion from semaglutide or tirzepatide. Retatrutide phase 3 TRIUMPH 1 trial

A transition is its own clinical question

Switching changes more than a molecule’s name. The previous medicine’s effects may persist, the new agent may act through additional pathways, and the patient’s glucose control, nutrition or symptoms may already be changing. A conversion table can conceal these interacting uncertainties.

A valid transition study would define who is eligible, what prior treatment they received, how the transition is supervised and what outcomes trigger reassessment. It would also follow people who stop because of adverse effects. Without those details, a claimed “protocol” is an extrapolation rather than a demonstrated care pathway.

Trial access and retail availability are different

FDA has warned about unapproved GLP-1-related products sold for human use under research labels. The presence of a product in an online catalog does not establish that it is the product used in a trial. FDA concerns with unapproved GLP 1 products

Someone dissatisfied with current treatment has a concrete discussion to have with the prescribing clinician: what outcome is falling short, whether side effects or adherence are contributing, and which approved alternatives or legitimate trials fit the situation. That conversation can also address the risks of abruptly changing treatment.

AXON’s educational role is to explain why direct transition evidence matters. We do not infer an exchange rate between medicines from separate weight-loss graphs or provide overlap, washout or escalation instructions. A reliable transition recommendation requires a specific patient, a verified product and clinical judgment supported by appropriate evidence.